Advances in primary glomerulonephritis.
Ellison B, Cader R, Willcocks L.
Br J Hosp Med (Lond). 2024 Jul 30;85(7):1-11. doi: 10.12968/hmed.2024.0044.
Primary glomerulonephritides.
Floege J, Amann K.
Lancet. 2016 May 14;387(10032):2036-48. doi: 10.1016/S0140-6736(16)00272-5. Epub 2016 Feb 25.
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants.
Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22.
Complement dysregulation in glomerulonephritis.
Kaartinen K, Safa A, Kotha S, Ratti G, Meri S.
Semin Immunol. 2019 Oct;45:101331. doi: 10.1016/j.smim.2019.101331. Epub 2019 Nov 9.
[Focal glomerulonephritis].
BERGAMINI A.
Minerva Med. 1957 Oct 10;48(81):3353-88.
[Focal glomerulonephritis].
FIASCHI E, CONTI C.
Rass Fisiopatol Clin Ter. 1951 Jan;23(1):25-54.
Néphropathie à IgA : cibler l’intestin pour traiter le rein.
Ammann S.
Rev Med Suisse. 2023 Dec 20;19(855):2419. doi: 10.53738/REVMED.2023.19.855.2419.
Sparsentan: First Approval.
Syed YY.
Drugs. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x.
Genetic insight into primary glomerulonephritis.
Wu MY, Chen YC, Chiu IJ, Wu MS.
Nephrology (Carlton). 2022 Aug;27(8):649-657. doi: 10.1111/nep.14074. Epub 2022 Jun 23.
Glomerulonephritis Histopathological Pattern Change.
AlYousef A, AlSahow A, AlHelal B, Alqallaf A, Abdallah E, Abdellatif M, Nawar H, Elmahalawy R.
BMC Nephrol. 2020 May 18;21(1):186. doi: 10.1186/s12882-020-01836-3.
